Imiquimod


CAS No. : 99011-02-6

(Synonyms: R 837)

99011-02-6
Price and Availability of CAS No. : 99011-02-6
Size Price Stock
100mg $66 In-stock
200mg $86 In-stock
500mg $151 In-stock
1 g Get quote
5 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-B0180
M.Wt: 240.30
Formula: C14H16N4
Purity: >98 %
Solubility: H2O : 2.64 mg/mL (ultrasonic;adjust pH to 2 with HCl);DMSO : 3.28 mg/mL (ultrasonic;warming;adjust pH to 7 with 1 M HCl;heat to 60°C);Methanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C)
Introduction of 99011-02-6 :

Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2]. IC50 & Target:toll-like receptor 7[1] In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Imiquimod (IMQ) can be used to induce psoriasis models[5].

Induction of psoriasis Model[5]
Background
Lmiquimod (IMQ) induces inflamed scaly skin lesions resembling plaque-type psoriasis. IMQ induces epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.
Specific Modeling Methods
Mice: BALB/c • male • 8-week-old
Administration: 3.125 mg/day • skin • 6 days
Note
IMQ cream preparation [7]:
(1) Prepare BM of lipids
STA and OA were melted at 75 °C followed by the addition of IMQ (3.5% of the BM, w/w) under continuous stirring.
Polysorbate 80 and stearoyl polyoxyl-32 glycerides at a 50:50 ratio were dispersed in water heated separately to 75 °C and added to the BM phase under continuous stirring.
(2) Prepare nanostructured lipid carriers (NLCs)
The mixture was then subjected to high-shear homogenization followed by ultrasonication.
The mixture was then rapidly cooled in an ice bath to allow the formation of NLCs.
Modeling Indicators
Behavior Observation: Induced the back skin of the mice started to display signs of erythema, scaling, and thickening.
Resulted in hyperproliferative keratinocytes and a disturbed epidermal differentiation (parakeratosis).

Your information is safe with us.

Our product is for R&D purpose only.